EGFR and neoplasm: Tumors with constitutively activating mutations downstream of EGFR no longer rely on ligand-stimulated EGFR activation to potentiate downstream signaling, thus rendering EGFR-targeted mAbs ineffective in inhibiting cell proliferation and tumor growth.